

Online Data Supplement

Asthma prescribing according to Arg16Gly beta-2 genotype: a randomized trial in adolescents

Tom Ruffles MD¹, Christina J Jones PhD², Colin Palmer PhD³, Steve Turner MD⁴, Jonathan Grigg MD⁵, Roger Tavendale PhD³, Fiona Hogarth MD⁶, Petra Rauchhaus⁷, Kristina Pilvinyte⁶, Romanie Hannah MD¹, Helen Smith MD^{8,9}, Roberta Littleford PhD¹⁰, Brian Lipworth MD¹¹, Somnath Mukhopadhyay PhD^{1,3}

Inclusion and Exclusion Criteria

Inclusion criteria

- a. Parent/Guardian/Participant is willing and able to give informed consent/assent
- b. Physician-diagnosed asthma
- c. Aged 12-18
- d. Taking inhaled corticosteroids (ICS) with/without second line controllers (i.e. LABA and/or LTRA)

Exclusion criteria

- a. Participant/Parent/Guardian is unwilling or unable to give informed consent/assent
- b. Participant has to be assessed as competent to provide consent.
- c. Known contraindication to montelukast or salmeterol
- d. On step 4 asthma control medication e.g. taking Theophylline, Slo-phylin, Uniphyllin

e. Other major airway or lung disease, e.g. chronic lung disease of prematurity, cystic fibrosis, and abnormal airway anatomy

f. Pregnant or lactating females (if participants become pregnant during the course of the study they will be asked to inform the research team and be withdrawn from the study)

g. Participating in another clinical trial (other than observational trials and registries) concurrently or within 30 days prior to screening for entry into this study

h. Unable to provide saliva/buccal cells for genotyping